Press Release

ASHP Foundation Releases Medication-Use Evaluation Resource Guide

Medication-use evaluations (MUEs) are an important quality improvement tool. Therefore, the ASHP Foundation convened a multidisciplinary Advisory Panel of experts to create the Medication-Use Evaluation Resource Guide: Andexanet Alfa in the Management of Life-Threatening Bleeds in Patients on Direct Factor Xa-Inhibitors.

The MUE Resource Guide, whose creation was supported by Alexion, applies the FOCUS-PDCA MUE framework from the ASHP Medication Use Evaluation Guidelines to a simulated MUE process and the creation of an MUE template for the use of andexanet alfa (andexanet), a specific reversal agent used in the management of life-threatening bleeding in patients who have been taking direct oral factor Xa inhibitors (DOACs). 

While the application of the FOCUS-PDCA framework in the resource guide is focused on a specific anticoagulant reversal agent, users can customize the included MUE templates to meet their organizational goals and apply the framework to other drugs and clinical scenarios.

The Advisory Panel found that applying the FOCUS-PDCA model enhances the rigor of MUEs and supports organizations to meet goals, including to optimize medication use, reduce process variation, decrease waste, and enhance value.

Join the ASHP Foundation and clinical pharmacy leaders on Tuesday, April 25, from noon-1:00 PM EDT for a live webinar, “Leveraging Medication-Use Evaluations to Optimize Care: Focus on Andexanet alfa.” Learn strategies to apply the ASHP Guidelines and FOCUS-PDCA to customize an MUE to the practice setting and patient and process considerations for using andexanet alfa in the management of life-threatening bleeding in patients on DOACs. This webinar is not for CE.

Access the Andexanet MUE Resource Guide and register for the April 25 webinar at ashpfoundation.org/mue.